Hudson Bay Capital Management’s AstraZeneca AZN Stock Holding History

Hudson Bay Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-222,437	Closed	-$34.1M	–	1201
2025 Q3	$34.1M	Buy	222,437 +64,128	+41%	+$9.71M	0.11%	152
2025 Q2	$22.1M	Buy	158,309 +156,291	+7,745%	+$21.9M	0.08%	196
2025 Q1	$297K	Sell	2,018 -157,982	-99%	-$22.9M	﹤0.01%	1099
2024 Q4	$21M	Buy	160,000 +142,500	+814%	+$19.9M	0.07%	237
2024 Q3	$2.73M	Buy	+17,500	New	+$2.82M	0.01%	529
2024 Q2	–	Sell	-235,462	Closed	-$31.9M	–	777
2024 Q1	$31.9M	Buy	235,462 +110,750	+89%	+$14.7M	0.18%	81
2023 Q4	$16.8M	Buy	+124,712	New	+$16.2M	0.11%	122
2022 Q1	–	Sell	-7,500	Closed	-$874K	–	1190
2021 Q4	$874K	Buy	+7,500	New	+$882K	0.01%	815
2014 Q3	–	Sell	-479,514	Closed	-$35.1M	–	210
2014 Q2	$35.6M	Buy	+479,514	New	+$34.7M	1.1%	29

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hudson Bay Capital Management's AZN Position: Q4 2025 in Review

Hudson Bay Capital Management sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 222,437 shares — an estimated $34.1M sold.

Hudson Bay Capital Management first reported a position in AZN in Q2 2014 and held it in 9 quarters. The position peaked at $35.6M in Q2 2014. 1,407 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Hudson Bay Capital Management reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 222,437 AstraZeneca shares in Q4 2025, an estimated $34.1M.
Hudson Bay Capital Management first reported a position in AstraZeneca in Q2 2014 and held it in 9 quarters.
Hudson Bay Capital Management's AstraZeneca position peaked at $35.6M in Q2 2014.
1,407 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Hudson Bay Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.